-+ 0.00%
-+ 0.00%
-+ 0.00%

Stifel Maintains Buy on Alnylam Pharmaceuticals, Lowers Price Target to $318

Benzinga·07/31/2026 13:39:57
语音播报
Stifel analyst Paul Matteis maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and lowers the price target from $444 to $318.